Cure for type 1 diabetes

The short version: there is no cure for type 1 diabetes in 2026. The evidence describes a set of halfway measures, each with serious trade-offs that are rarely fully disclosed.

The only approach that restores natural insulin production is transplanting beta cells, either as a whole pancreas or as isolated islets. Whole-pancreas transplant from a deceased donor gives about 84% graft survival at one year [1] and can keep a patient insulin-free for years. But the patient must take lifelong immunosuppression, with all its infection and cancer risks. The drugs themselves (tacrolimus, sirolimus) can damage kidneys and raise blood pressure. Islet transplantation is less invasive but outcomes are worse: under the best modern protocol, about 70% of patients were insulin-free at one year, dropping to 15% by five years [2]. Most must keep taking immunosuppression for the graft to survive, and the graft often fails slowly. The Edmonton trial reported 38 serious adverse events in a small cohort [2]. Neither pancreas nor islet transplant is available to most people because of donor scarcity.

Stem-cell-derived islets are the most talked-about "cure on the horizon." One 2023 case report of a single patient using her own reprogrammed stem cells showed dramatic improvement: HbA1c dropped from 8% to 4.76%, time in normal range went from 43% to over 98% at 75 days [9]. A company trial (VX-880) treating 12 patients with donor stem-cell islets reported that all survivors hit HbA1c below 7%, but 2 of the 12 died from causes the company said were unrelated [9]. The technology is early, the sample sizes tiny, and the safety profile in larger numbers is unknown. The 2021 commentary proposing transplantation into the eye's anterior chamber [3] remains a proposal, not data.

Immunotherapies aim to slow the disease, not reverse it. Teplizumab, the only FDA-approved drug for delaying type 1 diabetes, was tested in 76 high-risk relatives. It delayed the onset of clinical diabetes by about two years (median 48.4 months vs 24.4 months in the placebo group) [5, 8]. The trial was a single phase 2 study funded by the manufacturer, and the effect wanes over time; 43% of the teplizumab group still progressed to diabetes during follow-up [8]. The drug causes transient lymphocytopenia, skin rashes, and EBV reactivation [5]. Other immunotherapies (abatacept, rituximab, anti-thymocyte globulin) have shown small and temporary preservation of C-peptide in newly diagnosed patients, but no trial has shown a sustained cure [7, 6]. A 2014 study of mesenchymal stromal cells in 9 patients showed slightly better C-peptide at one year compared to controls, but the difference was minimal and the study tiny [4].

The question you should ask, if you or your child has type 1 diabetes: what is this intervention trading for its effect? Islet and pancreas transplant trade one disease for the burden of immunosuppression and its long-term cancer risk. Stem-cell islets trade unknown long-term safety for a chance at normal glucose levels. Immunotherapies trade drug toxicities for a few months or years of delay. None eliminates the need for insulin management, and none has been studied in the population that matters most to you: a fully unimmunosuppressed person who does not already have a kidney graft.

My call: there is no proven cure. The closest thing is a pancreas transplant, but it comes with a serious price. The evidence for a safe, durable cure simply does not exist yet.

Confidence: high — the gap between patient hope and what the data supports is large and clear.